Abstract
Tumors are invariably less well-oxygenated than the normal tissues from which they arise. Hypoxia-inducible factor-1 (HIF-1), a key transcriptional regulator, plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The expression, activity and stability of HIF-1 are not only induced in response to reduced oxygen availability but also modulated through PI-3K, MAPKs, autocrine signaling pathways, E3 ubiquitin ligases, and other regulators. The regulators and effects of HIF-1 in cancer have intensively provided us a new clue for the HIF-1 targeting anticancer therapy. This review evaluates the HIF-1 structure, the regulation mechanisms, the functions in cancer and corresponding anticancer strategies.
Keywords: Cancer, hypoxia-inducible factor-1, angiogenesis, Warburg effects, tumor microenvironment, therapy.
Current Cancer Drug Targets
Title:Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Volume: 10 Issue: 7
Author(s): Y. Li and D. Ye
Affiliation:
Keywords: Cancer, hypoxia-inducible factor-1, angiogenesis, Warburg effects, tumor microenvironment, therapy.
Abstract: Tumors are invariably less well-oxygenated than the normal tissues from which they arise. Hypoxia-inducible factor-1 (HIF-1), a key transcriptional regulator, plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The expression, activity and stability of HIF-1 are not only induced in response to reduced oxygen availability but also modulated through PI-3K, MAPKs, autocrine signaling pathways, E3 ubiquitin ligases, and other regulators. The regulators and effects of HIF-1 in cancer have intensively provided us a new clue for the HIF-1 targeting anticancer therapy. This review evaluates the HIF-1 structure, the regulation mechanisms, the functions in cancer and corresponding anticancer strategies.
Export Options
About this article
Cite this article as:
Li Y. and Ye D., Cancer Therapy By Targeting Hypoxia-Inducible Factor-1, Current Cancer Drug Targets 2010; 10(7) . https://dx.doi.org/10.2174/156800910793605857
DOI https://dx.doi.org/10.2174/156800910793605857 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel non-invasive Adjunctive Techniques for Early Oral Cancer Diagnosis and Oral Lesions Examination
Current Pharmaceutical Design Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Inhibition of SOX15 Sensitizes Esophageal Squamous Carcinoma Cells to Paclitaxel
Current Molecular Medicine Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia
CNS & Neurological Disorders - Drug Targets Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Alcohol and Smoking Mediated Oxidative Stress in Organ Toxicities: Role of Cytochrome P450 Systems
Mini-Reviews in Organic Chemistry Computer-Aided Drug Design Methodologies Toward the Design of Anti-Hepatitis C Agents
Current Topics in Medicinal Chemistry Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry